Lysocins: Bioengineered Antimicrobials That Deliver Lysins across the Outer Membrane of Gram-Negative Bacteria-Reference-Cited by-同舟云学术

Lysocins: Bioengineered Antimicrobials That Deliver Lysins across the Outer Membrane of Gram-Negative Bacteria

Published:2019-06 Issue:6 Volume:63 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Heselpoth Ryan D.¹,Euler Chad W.¹²³,Schuch Raymond⁴^ORCID,Fischetti Vincent A.¹

Affiliation:

1. Laboratory of Bacterial Pathogenesis and Immunology, The Rockefeller University, New York, New York, USA

2. Department of Medical Laboratory Sciences, Hunter College, CUNY, New York, New York, USA

3. Department of Microbiology and Immunology, Weill Cornell Medical College, New York, New York, USA

4. ContraFect Corporation, Yonkers, New York, USA

Abstract

The prevalence of multidrug-resistant Pseudomonas aeruginosa has stimulated development of alternative therapeutics. Bacteriophage peptidoglycan hydrolases, termed lysins, represent an emerging antimicrobial option for targeting Gram-positive bacteria.

Funder

The Rockefeller University

ContraFect Corporation

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00342-19

Reference50 articles.

1. Discovery, characterization and in vivo activity of pyocin SD2, a protein antibiotic from Pseudomonas aeruginosa

2. Bacterial and Clinical Characteristics of Health Care- and Community-Acquired Bloodstream Infections Due to Pseudomonas aeruginosa

3. Antibacterial-Resistant Pseudomonas aeruginosa : Clinical Impact and Complex Regulation of Chromosomally Encoded Resistance Mechanisms

4. WHO. 2017. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. World Health Organization, Geneva, Switzerland. http://www.who.int/medicines/publications/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf?ua=1.

5. Bacteriophage endolysins: A novel anti-infective to control Gram-positive pathogens

Cited by 73 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bacteriophage as a potential biotherapeutics to combat present-day crisis of multi-drug resistant pathogens;Heliyon;2024-09

2. Delivery of endolysin across outer membrane of Gram-negative bacteria using translocation domain of botulinum neurotoxin;International Journal of Antimicrobial Agents;2024-08

3. Development of novel antimicrobials with engineered endolysin LysECD7-SMAP to combat Gram-negative bacterial infections;Journal of Biomedical Science;2024-07-24

4. Phage therapy: an alternative treatment modality for MDR bacterial infections;Infectious Diseases;2024-07-17

5. Endolysins: a new antimicrobial agent against antimicrobial resistance. Strategies and opportunities in overcoming the challenges of endolysins against Gram-negative bacteria;Frontiers in Pharmacology;2024-05-20